Figure 2.
A summary of the biological effects induced by PPARγ agonist use in GBM in vitro and in vivo, and the drawbacks associated with PPARγ agonist use in clinical treatment of diabetes mellitus.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.